Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus for Native Kidney Volume Reduction in ADPKD Transplant Recipients
NCT02134899Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2014
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of everolimus in autosomal dominant polycystic kidney disease (ADPKD) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Total native kidney volume variation at 24 months. Started Oct 2014; status: completed.
02
Drugs
everolimus
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT02134899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02134899.